According to the complaint, following the Company's announcement on June 23, 2011 that the Company had received an inquiry from the U.S. Senate requesting information related to the Infuse product, following the June 28, 2011 publication of an entire issue of The Spine Journal was devoted to the Infuse product, including the conflicts of interest by researchers who had performed studies on Infuse and the underappreciated risks and side effects associated with Infuse, and following an August 3, 2011 announcement that the Company would publicly release Infuse data for Yale University ("Yale") researchers to conduct a review, the value of Medtronic stock declined significantly. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.